7-甲基咪唑并[1,2-a]吡啶-6-硼酸 | 957062-57-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 7-甲基咪唑并[1,2-a]吡啶-6-硼酸
• 英文名称: (7-methylimidazo[1,2-a]pyridin-6-yl)boronic acid
• 英文别名: (4,6-dimethylpyrimidin-5-yl)boronic acid；7-Methylimidazo[1,2-a]pyridine-6-boronic acid
• CAS: 957062-57-6
• 化学式: C₈H₉BN₂O₂
• mdl: MFCD09800890
• 分子量: 175.983
• InChiKey: OXZNXDWFAPHHTC-UHFFFAOYSA-N

物化性质

• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  57.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-甲基咪唑并[1,2-a]吡啶-6-硼酸 、 3-(4-bromophenyl)-N-(4-fluorophenyl)oxetane-3-carboxamide 在 dichloro[1,1'-bis(di-t-butylphosphino)ferrocene]palladium(II) 、 sodium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 生成 N-(4-fluorophenyl)-3-(4-(7-methylimidazo[1,2-a]pyridin-6-yl)phenyl)oxetane-3-carboxamide
  参考文献：
  名称：

  NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS

  摘要：

  本文披露了一种具有化学式（I）的化合物，或其药学上可接受的盐：本文还披露了本文披露的化合物在潜在的治疗或预防IDO相关疾病或紊乱中的用途。本文还披露了包含本文披露的化合物的组合物。本文还披露了组合物在潜在的治疗或预防IDO相关疾病或紊乱中的用途。

  公开号：

  US20190144433A1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QUE MODULATEURS DU TRANSPORT D'AMINES BIOGÈNES
  申请人：ANANTHAN SUBRAMANIAM

  公开号：WO2016090296A1

  公开（公告）日：2016-06-09

  The present disclosure relates to certain amine derivatives of fused bicyclic heterocycles that inhibit the amine reuptake function of the biogenic amine transporters, dopamine transporter (DAT), serotonin transporter (SERT) and norepinephrine transporter (NET). Compounds of the present disclosure are potent inhibitors of the reuptake of dopamine (DA), serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) with full or partial maximal efficacy. The compounds with partial maximal efficacy in inhibiting reuptake of all three biogenic amines are herein referred to as partial triple uptake inhibitors (PTRIs). Compounds of the present disclosure are useful for treating depression, pain and substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本公开涉及抑制生物胺转运体多巴胺转运体（DAT）、5-羟色胺转运体（SERT）和去甲肾上腺素转运体（NET）的某些融合双环杂环生物胺衍生物的化合物。本公开的化合物是多巴胺（DA）、5-羟色胺（5-HT）和去甲肾上腺素（NE）的重摄取的有效抑制剂，具有完全或部分最大效力。在抑制所有三种生物胺的重摄取中具有部分最大效力的化合物在此被称为部分三重摄取抑制剂（PTRIs）。本公开的化合物可用于治疗抑郁症、疼痛、物质滥用、物质滥用复发以及对可卡因、甲基苯丙胺、尼古丁和酒精等物质的成瘾。本摘要旨在作为在特定领域进行搜索的扫描工具，并不意在限制本发明。
• HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS
  申请人：ANANTHAN Subramaniam

  公开号：US20160159809A1

  公开（公告）日：2016-06-09

  The present disclosure relates to certain amine derivatives of fused bicyclic heterocycles that inhibit the amine reuptake function of the biogenic amine transporters, dopamine transporter (DAT), serotonin transporter (SERT) and norepinephrine transporter (NET). Compounds of the present disclosure are potent inhibitors of the reuptake of dopamine (DA), serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) with full or partial maximal efficacy. The compounds with partial maximal efficacy in inhibiting reuptake of all three biogenic amines are herein referred to as partial triple uptake inhibitors (PTRIs). Compounds of the present disclosure are useful for treating depression, pain and substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本公开涉及融合的双环杂环胺衍生物，其抑制生物胺转运体的胺重摄取功能，包括多巴胺转运体（DAT）、血清素转运体（SERT）和去甲肾上腺素转运体（NET）。本公开的化合物是多巴胺（DA）、血清素（5-羟色胺，5-HT）和去甲肾上腺素（NE）重摄取的有效抑制剂，具有完全或部分的最大功效。部分三重重摄取抑制剂（PTRIs）指部分最大功效抑制三种生物胺的重摄取的化合物。本公开的化合物可用于治疗抑郁症、疼痛和物质滥用以及物质滥用和对可卡因、甲基安非他明、尼古丁和酒精等物质成瘾的复发。该摘要旨在作为特定领域搜索的扫描工具，不旨在限制本发明。
• Discovery of biaryls as RORγ inverse agonists by using structure-based design
  作者：Istvan J. Enyedy、Noel A. Powell、Justin Caravella、Kurt van Vloten、Jianhua Chao、Daliya Banerjee、Douglas Marcotte、Laura Silvian、Andres McKenzie、Victor Sukbong Hong、Jason D. Fontenot

  DOI：10.1016/j.bmcl.2016.03.109

  日期：2016.5

  ROR gamma plays a critical role in controlling a pro-inflammatory gene expression program in several lymphocyte lineages including T cells, gamma delta T cells, and innate lymphoid cells. ROR gamma-mediated inflammation has been linked to susceptibility to Crohn's disease, arthritis, and psoriasis. Thus inverse agonists of ROR gamma have the potential of modulating inflammation. Our goal was to optimize two ROR gamma inverse agonists: T0901317 from literature and 1 that we obtained from internal screening. We used information from internal X-ray structures to design two libraries that led to a new biaryl series. (C) 2016 Elsevier Ltd. All rights reserved.